Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies
Clinical trial NCT01858181 · UNKNOWN
Trial details
- NCT number
- NCT01858181
- Sponsor
- Mentrik Biotech, LLC
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2015-12-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.